Abivax Stock Gains 3.46% After Obefazimod Phase 3 Shows >50% Remission
ABVX•Abivax shares rose 3.46% after Phase 3 trial results showed obefazimod achieved remission rates above 50% in ulcerative colitis patients, while several cancer cases during the study raised safety concerns. The stock remains below its 50- and 200-day moving averages, with momentum indicators pointing to continued technical weakness.
1. Phase 3 Trial Efficacy And Safety
Obefazimod met its primary endpoints in the Phase 3 ulcerative colitis trial, delivering remission rates exceeding 50% at key evaluation points. However, the emergence of several cancer cases among participants has introduced significant safety concerns and triggered investor scrutiny.
2. Stock Price Reaction And Technicals
Following the data release, Abivax stock jumped 3.46% on Thursday despite prevailing safety worries. Technical analysis shows the shares trading below both the 50-day and 200-day moving averages, while momentum indicators continue to signal potential downside.
3. Investor Concerns And Next Steps
Investors are weighing the strong efficacy data against the reported adverse events, seeking clarity on causality and regulatory impact. Abivax’s next milestones include detailed safety reviews and discussions with health authorities regarding the trial’s risk-benefit profile.
